For help on how to get the results you want, see our search tips.
343 results
-
List item
Human medicine European public assessment report (EPAR): Fulvestrant Mylan (updated)
fulvestrant, Breast Neoplasms
Date of authorisation: 08/01/2018,
, Revision: 3, Authorised, Last updated: 24/09/2020
-
List item
Human medicine European public assessment report (EPAR): Cometriq (updated)
cabozantinib, Thyroid Neoplasms
Date of authorisation: 21/03/2014,
, 
, 
, Revision: 19, Authorised, Last updated: 23/09/2020
-
List item
Veterinary medicine European public assessment report (EPAR): Inflacam (updated)
meloxicam, Horses, Dogs, Cats, Cattle, Pigs
Date of authorisation: 09/12/2011,, Revision: 11, Authorised, Last updated: 21/09/2020
-
List item
Veterinary medicine European public assessment report (EPAR): Rheumocam (updated)
meloxicam, Dogs, Horses, Cats, Cattle, Pigs
Date of authorisation: 10/01/2008,, Revision: 14, Authorised, Last updated: 21/09/2020
-
List item
Human medicine European public assessment report (EPAR): Strensiq (updated)
asfotase alfa, Hypophosphatasia
Date of authorisation: 28/08/2015,, , 
, Revision: 13, Authorised, Last updated: 21/09/2020
-
List item
Human medicine European public assessment report (EPAR): Pemetrexed medac (updated)
pemetrexed, Carcinoma, Non-Small-Cell Lung, Mesothelioma
Date of authorisation: 26/11/2015,, Revision: 6, Authorised, Last updated: 21/09/2020
-
List item
Human medicine European public assessment report (EPAR): Clopidogrel / Acetylsalicylic acid Mylan (updated)
acetylsalicylic acid, clopidogrel hydrogen sulfate, Acute Coronary Syndrome, Myocardial Infarction
Date of authorisation: 09/01/2020,, Revision: 1, Authorised, Last updated: 21/09/2020
-
List item
Human medicine European public assessment report (EPAR): Voriconazole Hikma (previously Voriconazole Hospira) (updated)
voriconazole, Bacterial Infections and Mycoses, Aspergillosis, Candidiasis
Date of authorisation: 27/05/2015,, Revision: 8, Authorised, Last updated: 21/09/2020
-
List item
Human medicine European public assessment report (EPAR): Sildenafil Actavis (updated)
sildenafil, Erectile Dysfunction
Date of authorisation: 10/12/2009,, Revision: 13, Authorised, Last updated: 18/09/2020
-
List item
Human medicine European public assessment report (EPAR): Bortezomib Sun (updated)
bortezomib, Multiple Myeloma
Date of authorisation: 22/07/2016,, Revision: 8, Authorised, Last updated: 17/09/2020
-
List item
Human medicine European public assessment report (EPAR): Arsenic trioxide Accord (updated)
Arsenic trioxide, Leukemia, Promyelocytic, Acute
Date of authorisation: 14/11/2019,, Revision: 2, Authorised, Last updated: 16/09/2020
-
List item
Human medicine European public assessment report (EPAR): Tolura (updated)
telmisartan, Hypertension
Date of authorisation: 04/06/2010,, Revision: 9, Authorised, Last updated: 16/09/2020
-
List item
Human medicine European public assessment report (EPAR): Azacitidine Mylan (updated)
azacitidine, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Date of authorisation: 27/03/2020,, Revision: 1, Authorised, Last updated: 16/09/2020
-
List item
Human medicine European public assessment report (EPAR): Ebilfumin (updated)
oseltamivir, Influenza, Human
Date of authorisation: 22/05/2014,, Revision: 12, Authorised, Last updated: 16/09/2020
-
List item
Human medicine European public assessment report (EPAR): Desloratadine Teva (updated)
desloratadine, Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Seasonal
Date of authorisation: 24/11/2011,, Revision: 15, Authorised, Last updated: 16/09/2020
-
List item
Human medicine European public assessment report (EPAR): Pioglitazone Actavis (updated)
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 15/03/2012,, Revision: 7, Authorised, Last updated: 16/09/2020
-
List item
Human medicine European public assessment report (EPAR): Ninlaro (updated)
ixazomib citrate, Multiple Myeloma
Date of authorisation: 21/11/2016,, , , Revision: 7, Authorised, Last updated: 15/09/2020
-
List item
Human medicine European public assessment report (EPAR): Cinacalcet Mylan (updated)
cinacalcet hydrochloride, Hyperparathyroidism, Secondary, Hypercalcemia
Date of authorisation: 19/11/2015,, Revision: 7, Authorised, Last updated: 14/09/2020
-
List item
Human medicine European public assessment report (EPAR): Leflunomide ratiopharm (updated)
leflunomide, Arthritis, Rheumatoid
Date of authorisation: 28/11/2010,, Revision: 14, Authorised, Last updated: 11/09/2020
-
List item
Human medicine European public assessment report (EPAR): Imatinib Accord (updated)
imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dermatofibrosarcoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome
Date of authorisation: 30/06/2013,, Revision: 16, Authorised, Last updated: 11/09/2020
-
List item
Human medicine European public assessment report (EPAR): Imatinib Actavis (updated)
imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Hypereosinophilic Syndrome, Dermatofibrosarcoma
Date of authorisation: 17/04/2013,, Revision: 12, Authorised, Last updated: 10/09/2020
-
List item
Human medicine European public assessment report (EPAR): Pramipexole Accord (updated)
pramipexole dihydrochloride monohydrate, Parkinson Disease, Restless Legs Syndrome
Date of authorisation: 29/09/2011,, Revision: 9, Authorised, Last updated: 09/09/2020
-
List item
Human medicine European public assessment report (EPAR): Ibandronic Acid Teva (updated)
ibandronic acid, Breast Neoplasms, Neoplasm Metastasis, Fractures, Bone, Osteoporosis, Postmenopausal
Date of authorisation: 17/09/2010,, Revision: 9, Authorised, Last updated: 09/09/2020
-
List item
Human medicine European public assessment report (EPAR): Temomedac (updated)
temozolomide, Glioma, Glioblastoma
Date of authorisation: 25/01/2010,, Revision: 14, Authorised, Last updated: 09/09/2020
-
List item
Human medicine European public assessment report (EPAR): Bortezomib Fresenius Kabi (updated)
bortezomib, Multiple Myeloma
Date of authorisation: 14/11/2019,, Revision: 2, Authorised, Last updated: 07/09/2020